Nagpur: After the hosting trials of various types of Covid-19 vaccines and some drugs delivered through injections, Nagpur has become a site for human trials from promising oral pills to cure patients with covid mild without hospitalization.
The Kingsway Hospital Infection Department is the host of the Molnupiravir trial, which can be the treatment of the first oral antivirus antivirus.
According to Merck who has developed this pill, it forces the Coronavirus SARS-COV-2 to mutate itself to death.
Dr.
Ashwini Took’s infectious disease specialist is the main researcher for trials that have begun at Kingsway Hospital.
Volunteer registration is still running because the number of covid patients with mild symptoms in Nagpur has fallen significantly.
Dr.
Tookee said that if approved, Molnupiravir could be a milestone in Covid-19 treatment.
“We accommodate the Double-Blind molnupiravir trial and still register patients.
It has been proven to be an excellent antivirus treatment so far.
We try it in patients who are not considered prioritized,” said Dr.
Took.
At least two Indian drug makers have independently tested generic molnupiravir in people with moderately July Covid-19Since.
They did not see “significant efficacy” in moderate patients.
But because the drug has shown a positive result for mild disease, the trial is being carried out in mild patients.
According to Dr.
Took, the pill can be proven to be useful even for infected people even after vaccination.
“There are growing concerns about the duration that will work vaccines and its efficacy of the new variant.
Many rich countries have started a dose of booster.
In temporary results for paths, this pill shows a 50% reduction in the risk of hospitalization.
Immediately, we can treat covid- 19 at home with this pill, “said Dr.
Took.
Molnupiravir is a generic oral drug that is affordable and can significantly reduce Covid-19 maintenance costs.
This can be a game-changer for low-income group countries.
As far as vaccines, they have been effective against moderate to severe illness.
But cases still come, although in small quantities, in Vidarbha, it implies that vaccines have not been able to prevent viral transmission.
Most patients detected are now asymptomatic or have mild symptoms.
They may benefit mostly if the oral pill is approved post-trial.
The trial for the first antiviral antivirus pill began in Nagpur
